Review Article
Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers
Table 3
Summary of discontinuation rate due to AEs and inefficacy at different time points among the included studies (12 comparative studies evidence).
| Registry | Study name | Intervention | | Discontinuation rate due to AEs (%) | Discontinuation rate due to inefficacy (%) | 6 m | 12 m | 18 m | 24 m | 36 m | 6 m | 12 m | 18 m | 24 m | 36 m |
| Biologic-naive | DREAM |
Flendrie et al. 2003 [1] | ADA | 94 | — | 11.0 | — | — | — | — | 11.0 | — | — | — | ETN | 14 | — | 7.0 | — | — | — | — | 7.0 | — | — | — | INF | 83 | — | 24.0 | — | — | — | — | 10.0 | — | — | — | LOHREN |
Marchesoni et al. 2009 [8] | ADA | 303 | — | — | — | — | 19.8 | — | — | — | — | 14.9 | ETN | 242 | — | — | — | — | 11.6 | — | — | — | — | 12.8 | INF | 519 | — | — | — | — | 20.4 | — | — | — | — | 20.0 |
| Mixed (biologic pretreated and biologic-naive) | SCQM |
Pan et al. 2009 [13] | ADA | 882 | 4.7 | 7.7 | 10.7 | 12.4 | 16.2 | — | — | — | — | — | ETN | 887 | 2.8 | 7.4 | 12.5 | 15.4 | 21.1 | — | — | — | — | — | INF | 595 | 4.7 | 10.0 | 14.8 | 20.3 | 24.7 | — | — | — | — | — | RABBIT |
Strangfeld et al. 2009 [14] | ADA + LEF | 174 | 12.0 | 21.6 | 26.0 | 27.3 | — | 13.1 | 23.8 | 28.0 | 31.2 | — | ADA + MTX | 566 | 12.8 | 18.8 | 23.8 | 25.0 | — | 12.8 | 18.5 | 22.4 | 24.6 | 32.4 | ETN + LEF | 144 | 8.5 | 15.7 | 19.3 | 22.1 | — | 9.6 | 19.9 | 22.6 | 30.6 | | ETN + MTX | 448 | 9.9 | 13.5 | 16.3 | 18.7 | 20.6 | 10.4 | 17.1 | 20.5 | 24.5 | 30.0 | INF + LEF | 76 | 17.8 | 27.8 | — | — | — | 16.1 | 25 | 37.4 | 43.5 | — | INF + MTX | 361 | 17.3 | 22.6 | 27.8 | 30.5 | 37.1 | 12.8 | 23.3 | 28.3 | 32.2 | — | | ADA | 8.3 (1622)
| 13.1 (1622)
| 16.9 (1622)
| 18.4 (1622)
| 16.2 (882)
| — | — | — | — | — | Pooled discontinuation rate | ETN | 5.5 (1479)
| 10.1 (1479)
| 14.3 (1479)
| 17.1 (1479)
| 20.9 (1335)
| — | — | — | — | — | | INF | 10.1 (1032)
| 15.8 (1032)
| 19.7 (956)
| 24.2 (956)
| 29.4 (956)
| — | — | — | — | — |
| Overall comparative evidence | | ADA | 8.3 (1622)
| 13.0 (1716)
| 16.9 (1622)
| 18.4 (1622)
| 17.3 (1185)
| 12.8 (740)
| 18.7 (834)
| 23.8 (740)
| 26.2 (740)
| 26.4 (869)
| Pooled discontinuation rate | ETN | 5.5 (1479) 2 | 10.1 (1493)
| 14.3 (1479)
| 17.1 (1479)
| 19.5 (1577)
| 10.1 (592)
| 17.5 (606)
| 20.9 (592)
| 26.0 (592)
| 23.9 (690)
| | INF | 10.1 (1032)
| 16.4 (1115)
| 19.7 (956)
| 24.2 (956)
| 26.2 (1475)
| 13.3 (437)
| 21.3 (520)
| 29.7 (437)
| 34.1 (437)
| 20.0 (519)
|
|
|
ADA: adalimumab; DREAM: Dutch Rheumatoid Arthritis Monitoring; ETN: etanercept; INF: infliximab; LEF: leflunomide; LOHREN: Lombardy Rheumatology Network; M: Months; MTX: methotrexate; RABBIT: rheumatoid arthritis observation of biologic therapy; SCQM: Swiss Clinical Quality Management in Rheumatic Diseases.
|